Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Hold at Wall Street Zen

Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other analysts have also recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Stock Down 0.5%

Shares of ENTA stock opened at $13.16 on Friday. The stock has a market cap of $382.69 million, a P/E ratio of -5.08 and a beta of 1.01. Enanta Pharmaceuticals has a 52 week low of $5.87 and a 52 week high of $17.15. The company’s fifty day simple moving average is $13.61 and its two-hundred day simple moving average is $13.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The business had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. On average, analysts anticipate that Enanta Pharmaceuticals will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP bought a new position in Enanta Pharmaceuticals in the 3rd quarter worth about $9,576,000. GSA Capital Partners LLP bought a new position in Enanta Pharmaceuticals in the 3rd quarter worth about $214,000. China Universal Asset Management Co. Ltd. grew its stake in Enanta Pharmaceuticals by 103.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 4,454 shares in the last quarter. AlphaQuest LLC raised its position in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $36,000. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.